

Monitoring all Drugs for a Specific Outcome in the Sentinel System

Judith C. Maro¹, Gerald Dal Pan², Jeffrey S. Brown¹,
Inna Dashevsky¹, Martin Kulldorff³

1. Harvard Medical School and Harvard Pilgrim Health Care Institute
2. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
3. Harvard Medical School and Brigham and Women's Hospital

ICPE Disclosure Slide

- Funding source: U.S. Food and Drug Administration
 - Mini-Sentinel Operations Center Response to Evaluation of Exposure/Outcome Associations, HHSF22301007T
 - Under contract: FDA HHSF223200910006I

- No relationships to disclose



What is

- A **signal detection / data-mining** method
- Scans electronic health data that are grouped into **hierarchical tree** structures
- Automatically adjusts for **multiple hypothesis testing**



<http://www.treescan.org>

What is an Outcome-Oriented Scan / DrugScan (1 Outcome: M Exposures)?



© MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED.


Total Nodes: 35,583 aggregate + 326,497 NDC codes


Surveillance Population

- Claims Data from 3 Data Partner Sites (2000-2014)
 - Not all sites had data back to 2000
- Males and Females ≥ 18 years with medical and drug coverage and incident outcome of interest
- Outcome of Interest
 - Angioedema

DrugScan Analytic Design and Statistics

- Case-Crossover Design (Self-Controlled)
- Incident Exposures or New “Starts” of Therapeutic
- Duration of Treatment Ignored
 - not “As Treated”
- Fixed and Variable Risk Window Scan Statistics





Conditional Tree-Based Scan Statistic

Hypotheses for Outcome-Oriented Scan

H_0 : The probability of an outcome after the dispensing of a drug is modified (conditioned) by the total number of events in the dataset across the observation window on that given day.


H_A : There are at least some time periods in the observation window when the probability of an outcome is higher
... after various adjustments


Angioedema Takeaways

- 1) Manageable Total Number of Alerts**
- 2) More Potential Misclassification of Disease Onset than Anticipated**

Results

Angioedema Cohort Attrition






- 110,785 pairs; 45,580 events at 3rd level
- On average, 2.4 incident dispensings per incident angioedema
- Day of the Week Effects

Angioedema Results

- 28 unique alerts at 0.05 level, 20 meaningfully different
 - 9 were angioedema treatments
 - e.g., Glucocorticosteroids, Hydroxyzine, Diphenhydramine
 - Rest were known positives or likely positives
 - ACE inhibitors, Bupropion, Simvastatin, Antibiotics

Angioedema Sensitivity Analyses

1. Pruned out all anti-histamines and other angioedema treatments (e.g., hydroxyzine, glucocorticosteroids)
 - Strong known positives remain with slight adjustment of time-to-event
 - Lose some known positives (adjusted conditional analysis)
 - Some new alerts



Tree-Temporal Alerts after Pruning

- 13 unique at 3rd level, 9 meaningfully different
- Some new antibiotics, ACEI Combos are statistically significant.
- Some alerts become not statistically significant at 0.05 level (e.g., simvastatin)

Angioedema Summary

1. Misclassification of Disease Onset is present
 - DESIGN: Prune out anti-histamines from the tree *a priori*
OR
 - DESIGN: Refine outcome definitions with MORE exclusions
OR
 - ANALYSIS: Prune based at analysis phase
2. Detects known positives without too many false positives

Acknowledgments

- DrugScan Team
 - Jeff Brown
 - Gerald Dal Pan
 - Inna Dashevsky
 - Martin Kulldorff
 - Andrew Petrone
 - Carolyn Balsbaugh
- DrugScan Protocol Reviewers
 - Mark Levenson
 - Rita Ouellet-Hellstrom
 - Simone Pinheiro

Q&A

You Are
(Not) Small



	Node Name	Node ID	Node Events	Window Start	Window End	Cases in Window	Expected Cases	Observed/Expected	Test Statistic	P-value
Angioedema, 3 rd level,	*Glucocorticosteroids***	221000	11127	1	8	3526	2324.33	1.52	274.41	1.00E-05
	Prednisone	2210004500	7009	1	7	2145	1314.87	1.63	222.79	1.00E-05
Tree-temporal, Conditional	Methylprednisolone	22100030	3893	1	8	1141	813.21	1.4	59.12	1.00E-05
	Methylprednisolone	2210003000	3891	1	8	1140	812.8	1.4	58.95	1.00E-05
-28 unique -20 different	Epinephrine	3890004000	3640	1	15	1925	1256.27	1.53	154.87	1.00E-05
	*H-2 Antagonists***	492000	1917	1	6	606	313.11	1.94	107.65	1.00E-05
Grey=Mis- classification of onset	Famotidine	4920003000	781	1	6	296	127.56	2.32	80.85	1.00E-05
	RanitidineHCl	4920002010	939	1	6	251	153.37	1.64	26.05	1.00E-05
Green=Known Positive	Hydroxyzine	57200040	2174	1	4	467	257.99	1.81	68.31	1.00E-05
	*Antianxiety Agents	Misc.***	572000	2268	1	4	472	269.15	1.75	62.47
Yellow=Likely Positive	HydroxyzineHCl	5720004010	1931	1	4	407	229.15	1.78	56.09	1.00E-05
	HydroxyzinePamoate	5720004020	243	1	10	104	60.23	1.73	13.04	0.00517
Pink=Likely False Positive	Sulfamethoxazole- Trimethoprim	1699000230	1812	3	13	641	431.96	1.48	44.16	1.00E-05
	*Antihistamines	Ethanolamines***	412000	169	1	6	73	27.6	2.64	25.61
	DiphenhydramineHCl	4120003010	159	1	6	70	25.97	2.7	25.39	1.00E-05
	Diphenhydramine	41200030	160	1	6	70	26.13	2.68	25.11	1.00E-05
	Lisinopril	3610003000	2169	2	8	502	372.83	1.35	20.24	1.00E-05
	*ACE Inhibitors***	361000	2649	2	8	594	455.34	1.3	19.33	2.00E-05
	MinocyclineHCl	400004010	199	12	19	63	28.26	2.23	15.78	0.0002
	BupropionHCl	5830004010	390	19	30	122	72.96	1.67	13.69	0.00254
	*Central Muscle Relaxants***	751000	1243	54	63	222	153.14	1.45	13.60	0.00279
	Levofloxacin	500003400	1115	1	3	161	104.99	1.53	12.84	0.00669
	Levofloxacin	5000034	1116	1	3	161	105.09	1.53	12.79	0.00718
	*Benzodiazepines***	571000	1491	41	63	531	425.52	1.25	12.16	0.01492
	Simvastatin	3940007500	802	42	54	188	129	1.46	11.82	0.0217
	*HMG CoA Reductase Inhibitors***	394000	2008	42	54	414	322.99	1.28	11.80	0.02207
	*Selective Serotonin Reuptake Inhibitors (SSRIs)***	581600	1044	32	59	469	372.2	1.26	11.66	0.02514
	Triazolam	6020104000	35	51	52	8	0.77	10.41	11.51	0.02985

Tree-Temporal Alerts after Pruning

Node Name	Node ID	Node Cases	Window Start	Window End	Cases in Window	Expected Cases	Observed/Expected	Test Statistic	P-Value
Sulfamethoxazole-Trimethoprim	1699000230	1812	3	12	598	373.06	1.6	57.51	1.00E-05
Lisinopril	3610003000	2169	1	8	590	402.72	1.47	38.23	1.00E-05
*ACE Inhibitors***	361000	2649	2	8	594	407.13	1.46	37.71	1.00E-05
Levofloxacin	500003400	1115	1	6	249	158.23	1.57	22.18	1.00E-05
Levofloxacin	5000034	1116	1	6	249	158.39	1.57	22.08	1.00E-05
*Fluoroquinolones***	50000	3159	1	6	588	447.95	1.31	20.02	1.00E-05
Minocycline HCl	400004010	199	15	19	44	15.95	2.76	16.60	3.00E-05
Clindamycin	16220020	770	1	7	189	127.28	1.48	13.02	0.0012
Clindamycin HCl	1622002010	769	1	7	188	127.1	1.48	12.71	0.0018
Bupropion HCl	5830004010	390	18	31	136	85.58	1.59	12.59	0.00199
Lisinopril & Hydrochlorothiazide	3699180255	748	2	9	188	128.84	1.46	11.90	0.00465
ACE Inhibitors & Thiazide/Thiazide-Like	36991802	814	2	9	201	139.95	1.44	11.74	0.00571
Triazolam	6020104000	35	51	52	8	0.94	8.48	10.05	0.0463

- 13 unique at 3rd level, 9 meaningfully different
- Some new antibiotics, ACEI Combos are statistically significant.
- Some alerts become not statistically significant at 0.05 level (e.g., simvastatin)